Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain langauage summary to help more people find, understand and use it.
Read the Original
This page is a summary of: Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts), European Respiratory Journal, September 2016, European Respiratory Society (ERS), DOI: 10.1183/13993003.congress-2016.pa992.
You can read the full text:
Be the first to contribute to this page